The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab
Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study. The TAILOR study is the first randomized, multicenter, prospective Phase III study evaluating the addition of cetuximab to FOLFOX in a RAS wt Chinese population and thus providing confirmatory data for the efficacy and safety of cetuximab plus FOLFOX versus FOLFOX alone.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
Recenti progressi in medicina - 113(2022), 6 vom: 12. Juni, Seite 19e-24e |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Lo studio TAILOR sancisce, nei pazienti con mCRC RAS wild-type, l’impiego in first line di FOLFOX in associazione a cetuximab |
|---|
| Beteiligte Personen: |
Colombo, Alfredo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cetuximab |
|---|
| Anmerkungen: |
Date Completed 28.06.2022 Date Revised 08.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1701/3827.38160 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342791354 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342791354 | ||
| 003 | DE-627 | ||
| 005 | 20231226014930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1701/3827.38160 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1142.xml |
| 035 | |a (DE-627)NLM342791354 | ||
| 035 | |a (NLM)35758127 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Colombo, Alfredo |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab |
| 246 | 3 | 3 | |a Lo studio TAILOR sancisce, nei pazienti con mCRC RAS wild-type, l’impiego in first line di FOLFOX in associazione a cetuximab |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.06.2022 | ||
| 500 | |a Date Revised 08.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study. The TAILOR study is the first randomized, multicenter, prospective Phase III study evaluating the addition of cetuximab to FOLFOX in a RAS wt Chinese population and thus providing confirmatory data for the efficacy and safety of cetuximab plus FOLFOX versus FOLFOX alone | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Organoplatinum Compounds |2 NLM | |
| 650 | 7 | |a Cetuximab |2 NLM | |
| 650 | 7 | |a PQX0D8J21J |2 NLM | |
| 650 | 7 | |a Leucovorin |2 NLM | |
| 650 | 7 | |a Q573I9DVLP |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 700 | 1 | |a Rosati, Gerardo |e verfasserin |4 aut | |
| 700 | 1 | |a Porretto, Concetta Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recenti progressi in medicina |d 1948 |g 113(2022), 6 vom: 12. Juni, Seite 19e-24e |w (DE-627)NLM000023124 |x 2038-1840 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2022 |g number:6 |g day:12 |g month:06 |g pages:19e-24e |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1701/3827.38160 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 2022 |e 6 |b 12 |c 06 |h 19e-24e | ||